Cloning and Functional Characterization of a σ Receptor from Rat Brain

Abstract: We have cloned a σ receptor from rat brain and established its functional identity using a heterologous expression system. The cloned cDNA (1,582 bp long) codes for a protein of 223 amino acids that possesses a single putative transmembrane domain. The amino acid sequence of the rat brain σ receptor is highly homologous to that of the σ receptor recently cloned from guinea pig liver and a human placental cell line but is not related to any other known mammalian receptors. When expressed in HeLa cells, the rat brain σ receptor cDNA leads to a two‐ to threefold increase in haloperidol binding, and this cDNA‐induced binding is sensitive to inhibition by several σ receptor‐specific ligands. Kinetic analysis using the heterologous expression system has revealed that the rat brain σ receptor interacts with haloperidol with an apparent dissociation constant (KD) of 3 nM. Functional expression of the cloned rat brain σ receptor in HeLa cells also leads to an increase in the binding of two other σ ligands, namely, (+)‐pentazocine and (+)‐3‐(3‐hydroxyphenyl)‐N‐(1‐propyl)piperidine (PPP). Pharmacological characterization of the cloned rat brain σ receptor reveals that it exhibits severalfold higher affinity for clorgyline than for 1,3‐di(2‐tolyl)guanidine, it interacts with progesterone and testosterone, and its interaction with PPP is markedly enhanced by phenytoin. In addition, transfection of MCF‐7 cells, which do not express type 1 σ receptor mRNA or activity, with the cloned rat brain cDNA leads to the appearance of haloperidol‐sensitive binding of (+)‐pentazocine, a selective type 1 σ receptor ligand. These data show that the cloned rat brain cDNA codes for a functional type 1 σ receptor. Northern blot analysis with poly(A)+ RNA isolated from various rat tissues has indicated that the σ receptor‐specific transcript, 1.6 kb in size, is expressed abundantly in liver and moderately in intestine, kidney, brain, and lung.

[1]  V. Ganapathy,et al.  Exon‐Intron Structure, Analysis of Promoter Region, and Chromosomal Localization of the Human Type 1 σ Receptor Gene , 1998, Journal of neurochemistry.

[2]  X. C. Lu,et al.  Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. , 1997, Life sciences.

[3]  G. Pasternak,et al.  Synthesis and characterization of [125I]3′-(−)-iodopentazocine, a selective σ1 receptor ligand , 1997 .

[4]  H. Glossmann,et al.  The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. , 1997, Trends in pharmacological sciences.

[5]  M. Kaghad,et al.  Emopamil-binding Protein, a Mammalian Protein That Binds a Series of Structurally Diverse Neuroprotective Agents, Exhibits Δ8-Δ7 Sterol Isomerase Activity in Yeast* , 1996, The Journal of Biological Chemistry.

[6]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[7]  G. Pasternak,et al.  Sigma antagonists potentiate opioid analgesia in rats , 1995, Neuroscience Letters.

[8]  V. Ganapathy,et al.  Cocaine-sensitive sigma-receptor and its interaction with steroid hormones in the human placental syncytiotrophoblast and in choriocarcinoma cells. , 1995, Endocrinology.

[9]  F. Tortella,et al.  σ receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures , 1995, Brain Research.

[10]  G. Pasternak,et al.  Selective antagonism of opioid analgesia by a sigma system. , 1994, The Journal of pharmacology and experimental therapeutics.

[11]  J. Witkin Pharmacotherapy of cocaine abuse: Preclinical development , 1994, Neuroscience & Biobehavioral Reviews.

[12]  W. Bowen,et al.  Characterization of a (+)-azidophenazocine-sensitive sigma receptor on splenic lymphocytes. , 1993, Journal of immunology.

[13]  E. Schmid,et al.  Identification of a 27-kDa high affinity phenylalkylamine-binding polypeptide as the sigma 1 binding site by photoaffinity labeling and ligand-directed antibodies. , 1993, Molecular pharmacology.

[14]  R. Quirion,et al.  Evidence for in vivo interactions between neuropeptide Y-related peptides and sigma receptors in the mouse hippocampal formation , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  H. Glossmann,et al.  Biochemical characterization of a 22-kDa high affinity antiischemic drug-binding polypeptide in the endoplasmic reticulum of guinea pig liver: potential common target for antiischemic drug action. , 1993, Molecular pharmacology.

[16]  D. DeHaven-Hudkins,et al.  Allosteric modulation of ligand binding to [3H](+)pentazocine-defined sigma recognition sites by phenytoin. , 1993, Life sciences.

[17]  G. Debonnel,et al.  Neuropeptide Y potentiates the N-methyl-D-aspartate response in the CA3 dorsal hippocampus. II. Involvement of a subtype of sigma receptor. , 1992, The Journal of pharmacology and experimental therapeutics.

[18]  H. Ericson,et al.  Subchronic treatment of rats with remoxipride fails to modify sigma binding sites in the brain. , 1992, European journal of pharmacology.

[19]  W. Bowen,et al.  A proposal for the classification of sigma binding sites. , 1992, Trends in pharmacological sciences.

[20]  S. Snyder,et al.  σ Receptors: From Molecule to Man , 1991 .

[21]  T. Su,et al.  Solubilization and characterization of haloperidol-sensitive (+)-[3H]SKF-10,047 binding sites (sigma sites) from rat liver membranes. , 1991, The Journal of pharmacology and experimental therapeutics.

[22]  A. Mahboubi,et al.  Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. , 1991, Molecular pharmacology.

[23]  J. Musacchio,et al.  SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorphan and sigma ligands to guinea pig brain. , 1991, Life sciences.

[24]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[25]  P. Rivière,et al.  Neuropeptide Y and JO 1784, a selective sigma ligand, alter intestinal ion transport through a common, haloperidol-sensitive site. , 1990, European journal of pharmacology.

[26]  W. Bowen,et al.  A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain , 1990, Brain Research.

[27]  C. Nemeroff,et al.  Sigma receptor "antagonist" BMY 14802 increases neurotensin concentrations in the rat nucleus accumbens and caudate. , 1990, The Journal of pharmacology and experimental therapeutics.

[28]  C. Montigny,et al.  N-methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors , 1990 .

[29]  J. Cadet,et al.  Sigma receptor blockade by BMY 14802 affects enkephalinergic and tachykinin cells differentially in the striatum of the rat. , 1990, European journal of pharmacology.

[30]  Y. Itzhak,et al.  Sigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders. , 1990, Life sciences.

[31]  B. Martin,et al.  Neuropeptide Y and Peptide YY Interact with Rat Brain Sigma and PCP Binding Sites , 1990, European journal of pharmacology.

[32]  E. London,et al.  Cerebral metabolic effects of σ ligands in the rat , 1989, Brain Research.

[33]  J. Musacchio,et al.  Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. , 1989, Molecular pharmacology.

[34]  J. Musacchio,et al.  High affinity dextromethorphan binding sites in guinea pig brain: further characterization and allosteric interactions. , 1988, The Journal of pharmacology and experimental therapeutics.

[35]  M. Kavanaugh,et al.  Identification of the binding subunit of the sigma-type opiate receptor by photoaffinity labeling with 1-(4-azido-2-methyl[6-3H]phenyl)-3-(2-methyl[4,6-3H]phenyl)guanidine. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[36]  F. J. White,et al.  Electrophysiological effects of BMY 14802, a new potential antipsychotic drug, on midbrain dopamine neurons in the rat: acute and chronic studies. , 1988, The Journal of pharmacology and experimental therapeutics.

[37]  G. Vogeli,et al.  Amplification, storage, and replication of libraries. , 1987, Methods in enzymology.

[38]  D. Eisenberg,et al.  Analysis of membrane and surface protein sequences with the hydrophobic moment plot. , 1984, Journal of molecular biology.

[39]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[40]  W. Bowen,et al.  Sigma-i and Sigma-2 Receptors Are Expressed in a Wide Variety of Human and Rodent Tumor Cell Lines , 2022 .